Translate

Wednesday, May 29, 2019

thumbnail

PFNX Pfenex Inc. gains 16% May 29, 2019

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. The company also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia. It has collaboration agreements with Hospira, Inc. and Jazz Pharmaceuticals Ireland Limited. Pfenex Inc. is headquartered in San Diego, California.http://www.priceseries.com/trade/PFNX-Pfenex-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019050820190529.html

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive